Aprea Therapeutics, Inc.

Historical 13F Holders

Symbol
APRE
CUSIP
03836J201
All holders as of
Q2 2026
Type
Equity
Class
COM NEW
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 03836J201 since 12/18/2024, newest first.

Filer % of Class Filed
Lytton Laurence W 13G/A Amendment 1 3.2% 8/13/2026
Event 6/30/2026
Vestal Point Capital, LP 13G
9.9% 5/15/2026
Event 3/31/2026
Nantahala Capital Management, LLC 13G/A Amendment 1
4.5% 2/13/2026
Event 12/31/2025
Lytton Laurence W 13G 9.9% 11/17/2025
Event 11/13/2025
Sio Capital Management, LLC 13G/A Amendment 4 1.9% 11/12/2025
Event 9/30/2025
Sio Capital Management, LLC 13G/A Amendment 3 5.1% 8/13/2025
Event 6/30/2025
Stonepine Capital Management, LLC 13G/A Amendment 2
4.3% 5/14/2025
Event 3/31/2025
Sio Capital Management, LLC 13G/A Amendment 2 5.0% 4/8/2025
Event 3/31/2025
Stonepine Capital Management, LLC 13G/A Amendment 1
5.1% 2/13/2025
Event 12/31/2024
Nantahala Capital Management, LLC 13G
7.3% 11/14/2024
Event 9/30/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q2 28 2.58 M $2.07 M
2026 Q1 22 2.24 M $1.71 M
2025 Q4 22 1.70 M $1.45 M
2025 Q3 23 1.62 M $2.39 M
2025 Q2 24 1.82 M $3.07 M
2025 Q1 27 1.95 M $3.78 M
2024 Q4 27 2.08 M $6.83 M
2024 Q3 24 2.14 M $5.88 M
2024 Q2 32 2.32 M $9.44 M
2024 Q1 25 1.68 M $11.1 M
2023 Q4 23 944 k $4.44 M
2023 Q3 22 877 k $3.66 M
2023 Q2 20 882 k $2.78 M
2023 Q1 17 848 k $3.77 M